WO2017175184A1 - Procédé de préparation de la forme amorphe d'idélalisib - Google Patents
Procédé de préparation de la forme amorphe d'idélalisib Download PDFInfo
- Publication number
- WO2017175184A1 WO2017175184A1 PCT/IB2017/052002 IB2017052002W WO2017175184A1 WO 2017175184 A1 WO2017175184 A1 WO 2017175184A1 IB 2017052002 W IB2017052002 W IB 2017052002W WO 2017175184 A1 WO2017175184 A1 WO 2017175184A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- idelalisib
- amorphous form
- temperature
- solution
- carried out
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Abstract
La présente invention concerne de manière générale des procédés de préparation de la forme amorphe d'Idélalisib et une composition pharmaceutique comprenant cette dernière.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641012262 | 2016-04-07 | ||
IN201641012262 | 2016-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017175184A1 true WO2017175184A1 (fr) | 2017-10-12 |
Family
ID=60000968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/052002 WO2017175184A1 (fr) | 2016-04-07 | 2017-04-07 | Procédé de préparation de la forme amorphe d'idélalisib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017175184A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10370376B2 (en) * | 2015-04-15 | 2019-08-06 | Alnova Pharmaceuticals, Ltd. | Amorphous substance of Idelalisib and preparation method therefor |
WO2019178596A1 (fr) | 2018-03-16 | 2019-09-19 | Johnson Matthey Public Limited Company | Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013134288A1 (fr) * | 2012-03-05 | 2013-09-12 | Gilead Calistoga Llc | Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one |
WO2015014315A1 (fr) * | 2013-08-01 | 2015-02-05 | 杭州普晒医药科技有限公司 | Forme cristalline d'inhibiteur et son procédé de préparation et son utilisation |
WO2015092810A2 (fr) * | 2013-11-20 | 2015-06-25 | Cadila Healthcare Limited | Forme amorphe d'idélalisib |
WO2015095605A1 (fr) * | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one |
-
2017
- 2017-04-07 WO PCT/IB2017/052002 patent/WO2017175184A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013134288A1 (fr) * | 2012-03-05 | 2013-09-12 | Gilead Calistoga Llc | Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one |
WO2015014315A1 (fr) * | 2013-08-01 | 2015-02-05 | 杭州普晒医药科技有限公司 | Forme cristalline d'inhibiteur et son procédé de préparation et son utilisation |
WO2015092810A2 (fr) * | 2013-11-20 | 2015-06-25 | Cadila Healthcare Limited | Forme amorphe d'idélalisib |
WO2015095605A1 (fr) * | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10370376B2 (en) * | 2015-04-15 | 2019-08-06 | Alnova Pharmaceuticals, Ltd. | Amorphous substance of Idelalisib and preparation method therefor |
WO2019178596A1 (fr) | 2018-03-16 | 2019-09-19 | Johnson Matthey Public Limited Company | Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation |
US11358966B2 (en) | 2018-03-16 | 2022-06-14 | Johnson Matthey Public Limited Company | Pyridine or N,N-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10738038B2 (en) | Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof | |
US11760757B2 (en) | Solid state forms of lumateperone ditosylate salt | |
US10035802B2 (en) | Solid state forms of ibrutinib | |
EP3337485B1 (fr) | Formes cristallines d'ibrutinib | |
EP3218351B1 (fr) | Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377 | |
US20090076272A1 (en) | Polymorphs of eszopiclone malate | |
JP2021105003A (ja) | 多形体及びキナゾリニル誘導体の調製プロセス | |
US20080167477A1 (en) | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same | |
US9624207B2 (en) | Polymorphs of azilsartan medoxomil | |
WO2019186522A1 (fr) | Procédé amélioré de préparation du lopinavir et de ses intermédiaires | |
WO2017175184A1 (fr) | Procédé de préparation de la forme amorphe d'idélalisib | |
WO2011080651A2 (fr) | Formes polymorphes de fébuxostat | |
WO2011153221A1 (fr) | Formes d'ixabepilone à l'état solide | |
WO2014128728A2 (fr) | Formes solides de cabazitaxel et leurs procédés de préparation | |
US20210300950A1 (en) | Solid state forms of ixazomib citrate | |
WO2020234817A1 (fr) | Formes polymorphes d'apalutamide et leur préparation | |
CZ2003956A3 (cs) | Způsob purifikace pravastatinu nebo jeho farmaceuticky přijatelné soli | |
US8993786B2 (en) | Crystalline fosamprenavir calcium and process for the preparation thereof | |
EA030947B1 (ru) | Способ крупномасштабного производства 1-изопропил-3-{5-[1-(3-метоксипропил)пиперидин-4-ил]-[1,3,4]оксадиазол-2-ил}-1h-индазола оксалата | |
WO2023141082A1 (fr) | Formes à l'état solide de tipifarnib et leur procédé de préparation | |
US20110281928A1 (en) | Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof | |
WO2024033632A1 (fr) | Procédé amélioré de préparation d'analogues de phosphonate antiviraux | |
WO2015166466A1 (fr) | Forme cristalline d'acétate de saxagliptine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17778773 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17778773 Country of ref document: EP Kind code of ref document: A1 |